Ring Carbon Is Shared By Three Of The Cyclos Patents (Class 514/288)
-
Publication number: 20040209909Abstract: Composition of matter for application to a body surface or membrane to administer pergolide by permeation through the body surface or membrane, the composition comprising pergolide to be administered, at a therapeutically effective rate, alone or in combination with a permeation enhancer or mixture. Also disclosed are drug delivery devices containing the pergolide or pergolide and enhancer composition and methods for the transdermal administration of the pergolide and pergolide/enhancer composition.Type: ApplicationFiled: April 9, 2002Publication date: October 21, 2004Inventors: Su Il Yum, Melinda K. Nelson, Patricia S. Campbell
-
Publication number: 20040209910Abstract: The invention provides methods for preparing amorphous physical form of cabergoline, and solvate form A of cabergoline useful in the preparation of the first mentioned physical form. A method for treating a prolactin disorder with medicaments prepared from amorphous physical form of cabergoline and solvate form A of cabergoline is also disclosed.Type: ApplicationFiled: April 20, 2004Publication date: October 21, 2004Inventors: Arie Gutman, Boris Tishin, Alex Vilenski, Albay Agazade, Boris Pertzikov, Gennady Nisnevich
-
Publication number: 20040198759Abstract: The invention provides aporphine and oxoaporphine compounds that have endothelial nitric oxide synthase (eNOS) maintaining or enhancing activities and may be used to manufacture a medicaments for preventing or treating ischemic diseases in human and mammal, and the ischemic diseases may include ischemic cerebral apoplexy, ischemic cerebral thrombosis, ischemic cerebral embolism, hypoxic ischemic encephlopathy, ischemic cardiac disease or ischemic enteropathy etc.Type: ApplicationFiled: April 2, 2004Publication date: October 7, 2004Inventors: MingJai Su, ShoeiSheng Lee
-
Patent number: 6800635Abstract: Crystalline form II of cabergoline, a pharmaceutical composition containing it and a process for its preparation are disclosed. The process may comprise crystallization from s solution of raw cabergoline in an organic solvent at low temperatures or submitting to a slurry procedure a mixture of cabergoline forms I and II in a solvent at a temperature below 30° C.Type: GrantFiled: October 31, 2003Date of Patent: October 5, 2004Assignee: Pharmacia Italia, S.p.A.Inventors: Attilio Tomasi, Stefania Magenes, Giuliano Ramella, Mario Ungari, Marco Pandolfi
-
Patent number: 6777406Abstract: The present invention is directed to certain novel compounds represented by structural Formula (I) or pharmaceutically acceptable salt forms thereof, wherein is R1, R6a, R6b, R7, R8, R9, X, b, m, and n are described herein. The invention is also concerned with pharmaceutical formulations comprising these novel compounds as active ingredients and the use of the novel compounds and their formulations in the treatment of certain disorders. The compounds of this invention are serotonin agonists and antagonists and are useful in the control or prevention of central nervous system disorders including obesity, anxiety, depression, psychosis, schizophrenia, sleep disorders, sexual disorders, migraine, conditions associated with cephalic pain, social phobias, and gastrointestinal disorders such as dysfunction of the gastrointestinal tract motility.Type: GrantFiled: December 19, 2001Date of Patent: August 17, 2004Assignee: Bristol-Myers Squibb Pharma CompanyInventors: John M. Fevig, Ian S. Mitchell, Taekyu Lee, Wenting Chen, Joseph Cacciola
-
Patent number: 6777405Abstract: Duplex polynucleotides containing damage or errors are detected with hindered intercalating compounds which are capable of intercalating only in the presence of such damage or error. Conditions characterized by the presence of polynucleotide errors or damage are treated with such compounds that are capable of catalyzing polynucleotide cleavage with light.Type: GrantFiled: September 3, 2002Date of Patent: August 17, 2004Assignee: California Institute of TechnologyInventors: Jacqueline K. Barton, Brian A. Jackson, Brian P. Hudson
-
Publication number: 20040116456Abstract: A therapeutic drug for psychoneurotic disorders, which is useful for therapies of psychoneurotic disorders, especially restless legs syndrome is disclosed. The therapeutic drug for psychoneurotic disorders according to the present invention comprises as an effective ingredient an opioid &kgr; receptor agonist compound (excluding pentazocine) such as (−)-17-(cyclopropylmethyl)-3,14&bgr;-dihydroxy-4,5&agr;-epoxy-6&bgr;[N-methyl-trans-3-(3-furyl)acrylamide]morphinan hydrochloric acid salt.Type: ApplicationFiled: September 29, 2003Publication date: June 17, 2004Inventors: Hiroo Kumagai, Jun Utsumi
-
Publication number: 20040110694Abstract: A novel solid pharmaceutical dispersion that improves the bioavailability of poorly water soluble drugs is produced by combining the drug with a polymer carrier such as polyvinylpyrrolidone. The drug is combined with the carrier without the need for using organic solvents or melting temperatures (fusion) through the use of a transition compound such as polyethylene glycol which partially solubilizes the drug and/or plasticizes the polymer.Type: ApplicationFiled: December 3, 2003Publication date: June 10, 2004Inventors: Isaac Ghebre-Sellassie, Robert Reisch, Riten Parikh, Mahdi B. Fawzi, Russell U. Nesbitt
-
Publication number: 20040101550Abstract: Use of a transdermal therapeutic system (TTS) comprising a pharmaceutical layer containing at least one matrix having an active ingredient and/or an active ingredient reservoir; a diffusion barrier that is permeable to said active ingredient and arranged on the skin side of the active ingredient reservoir; and an ergoline derivative or salt thereof as an active ingredient for producing an agent for obtaining and maintaining the circadian rhythm under dopamine therapy.Type: ApplicationFiled: July 7, 2003Publication date: May 27, 2004Inventors: Fred Windt-Hanke, Clemens Gunther, Reinhard Horowski, Johannes Tack
-
Publication number: 20040092544Abstract: The invention relates to the use of a dopamine agonist in the form of an agent consisting of at least two spatially discrete compositions, of which one is a transdermal therapeutic system (TTS) containing the dopaminergic agent and another one or more are preparations for oral and/or parenteral application containing that same dopaminergic agent for the treatment of dopaminergically treatable diseases with the following elements: a) the TTS is continuously applied, b) within the duration of application in a) the composition for oral or parenteral dosage is administered.Type: ApplicationFiled: July 3, 2003Publication date: May 13, 2004Inventors: Reinhard Horowski, Johannes Tack
-
Publication number: 20040087561Abstract: Bombesin receptor antagonists have been found to be useful in the treatment of sexual dysfunction in both males and females. They may be selective BB1 antagonists or mixed BB1/BB2 antagonists. Combinations are disclosed of bombesin receptor antagonists with a range of other active compounds, for example PDE5 inhibitors, NEP inhibitors and lasofoxifene.Type: ApplicationFiled: December 4, 2003Publication date: May 6, 2004Inventors: Maria Isabel Gonzalez, Michael Higginbottom, Alisdair MArk Naylor, Robert Denham Pinnock, Martyn Clive Pritchard, Herman Thijs Stock, Pieter Hadewijn Van Der Graaf, Christopher Peter Wayman
-
Patent number: 6727242Abstract: The present invention relates generally to pharmacological methods for the prevention of amelioration of sleep-related breathing disorders via administration of agents or combinations of agents that possess serotonin-related pharmacological activity.Type: GrantFiled: December 14, 2001Date of Patent: April 27, 2004Assignee: The Board of Trustees of the University of IllinoisInventors: Miodrag Radulovacki, David W. Carley
-
Publication number: 20040072855Abstract: Crystalline form II of cabergoline, a pharmaceutical composition containing it and a process for its preparation are disclosed. The process may comprise crystallization from s solution of raw cabergoline in an organic solvent at low temperatures or submitting to a slurry procedure a mixture of cabergoline forms I and II in a solvent at a temperature below 30° C.Type: ApplicationFiled: October 31, 2003Publication date: April 15, 2004Applicant: Pharmacia Italia, S.p.A.Inventors: Attilio Tomasi, Stefania Magenes, Giuliano Ramella, Mario Ungari, Marco Pandolfi
-
Publication number: 20040043977Abstract: Disclosed are compounds which inhibit &bgr;-amyloid peptide release and/or its synthesis, and, accordingly, have utility in treating Alzheimer's disease. Also disclosed are pharmaceutical compositions comprising a compound which inhibits &bgr;-amyloid peptide release and/or its synthesis as well as methods for treating Alzheimer's disease both prophylactically and therapeutically with such pharmaceutical compositions.Type: ApplicationFiled: January 6, 2003Publication date: March 4, 2004Inventors: Jing Wu, Jay S. Tung, Eugene D. Thorsett, Michael A. Pleiss, Jeffrey S. Nissen, Jeffrey Neitz, Lee H. Latimer, Varghese John, Stephen Freedman, Thomas C. Britton, James E. Audia, Jon K. Reel, Thomas E. Mabry, Bruce A. Dressman, Cynthia L. Cwi, James J. Droste, Steven S. Henry, Stacey L. McDaniel, William Leonard Scott, Russell D. Stucky, Warren J. Porter
-
Patent number: 6699852Abstract: The present invention is directed to certain novel compounds represented by structural Formula (I) or pharmaceutically acceptable salt forms thereof, wherein R1, R5, R6, R7, R8, R9, X, b, k, and n, and the dashed lines are described herein. The invention is also concerned with pharmaceutical formulations comprising these novel compounds as active ingredients and the use of the novel compounds and their formulations in the treatment of certain disorders. The compounds of this invention are serotonin agonists and antagonists and are useful in the control or prevention of central nervous system disorders including obesity, anxiety, depression, psychosis, schizophrenia, sleep disorders, sexual disorders, migraine, conditions associated with cephalic pain, social phobias, and gastrointestinal disorders such as dysfunction of the gastrointestinal tract motility.Type: GrantFiled: December 19, 2001Date of Patent: March 2, 2004Assignee: Bristol-Myers Squibb Pharma CompanyInventors: Albert Robichaud, John M. Fevig, Ian S. Mitchell, Taekyu Lee, Wenting Chen, Joseph Cacciola
-
Publication number: 20040028723Abstract: The invention relates to the use of a transdermal therapeutic system (TTS) comprising a medicinal layer, which contains at least one matrix comprising an active ingredient and/or an active ingredient reservoir and a diffusion barrier situated on the skin side of the active ingredient reservoir and permeable to active ingredients, in addition to, an ergoline-derivative or physiologically compatible salt with an acid thereof, as an active ingredient, for producing a means for treating the restless-legs-syndrome.Type: ApplicationFiled: July 21, 2003Publication date: February 12, 2004Inventors: Reinhard Horowski, Johannes Tack, Adalbert Engfer
-
Patent number: 6680327Abstract: Crystalline form VII of cabergoline, a pharmaceutical composition containing it and a process for its preparation are disclosed. The process may comprise a slurry procedure using form I or mixture of forms I and VII of cabergoline in a solvent at a temperature above 30° C.Type: GrantFiled: September 18, 2002Date of Patent: January 20, 2004Assignee: Pharmacia Italia SpAInventors: Ilaria Candiani, Raffaella Budelli, Marco Pandolfi, Mario Ungari
-
Patent number: 6673806Abstract: Crystalline form II of cabergoline, a pharmaceutical composition containing it and a process for its preparation are disclosed. The process may comprise crystallization from a solution of raw cabergoline in an organic solvent at low temperatures or submitting to a slurry procedure a mixture of cabergoline Forms I and II in a solvent at a temperature below about 30° C.Type: GrantFiled: January 16, 2003Date of Patent: January 6, 2004Assignee: Pharmacia Italia S.p.A.Inventors: Attilio Tomasi, Stefania Magenes, Giuliano Ramella, Mario Ungari, Marco Pandolfi
-
Patent number: 6664263Abstract: The invention provides imidazoacridone compounds of general formula (1) which have cytotoxic and anti-tumor activity. The invention also provides methods of preparing the compounds, and methods of using the compounds for the treatment of cancer or other mammalian diseases characterized by undesirably high levels of cell proliferation. The compounds of the invention are also expected to have utility as research tools.Type: GrantFiled: March 3, 2003Date of Patent: December 16, 2003Assignee: The United States of America as represented by the Department of Health and Human ServicesInventors: Wieslaw M. Cholody, Teresa Kosakowska-Cholody, Christopher J. Michejda
-
Publication number: 20030225031Abstract: Methods and compositions are disclosed that provide acetylcholinesterase inhibitors for the prevention and treatment of diseases and disorders of the central nervous system, including dementia such as Alzheimer's disease, to the central nervous system via intranasal delivery. The methods and compositions of the present invention provide therapeutic concentrations of the acetylcholinesterase inhibitor in the cerebrospinal fluid of a mammal without the attendant disadvantages, risks and side effects of oral or injection delivery.Type: ApplicationFiled: May 15, 2003Publication date: December 4, 2003Inventor: Steven C. Quay
-
Publication number: 20030219473Abstract: Purified soy phosphatidylserine is used to make cochleates. The cochleates contain at least about 75% soy phosphatidylserine and optionally a bioactive load. A preferred cochleate contains the antifungal agent amphotericin B.Type: ApplicationFiled: November 26, 2002Publication date: November 27, 2003Inventors: Leila Zarif, Feng Tan
-
Publication number: 20030212085Abstract: The present invention relates to the treatment of neuromuscular disorders and, more specifically, to the use of apomorphine, bromocriptine, pergolide, ropinirole, octahydropyrazolo[3,4-g]quinolines, and trans-(±)-substituted-5,5a,6,7,8,9-,9a,10-octahydropyrimido[4,5g]quinolines, and their pharmaceutically acceptable salts to treat, or to prepare a medicament for treating, symptoms of fibromyalgia syndrome and chronic fatigue syndrome.Type: ApplicationFiled: October 18, 2002Publication date: November 13, 2003Inventors: Robert B. McCall, Robert Clyde Marshall
-
Publication number: 20030203916Abstract: The invention provides imidazoacridone compounds of general formula (1) which have cytotoxic and anti-tumor activity. The invention also provides methods of preparing the compounds, and methods of using the compounds for the treatment of cancer or other mammalian diseases characterized by undesirably high levels of cell proliferation. The compounds of the invention are also expected to have utility as research tools.Type: ApplicationFiled: March 3, 2003Publication date: October 30, 2003Inventors: Wieslaw M Cholody, Teresa Kosalowska-Cholody, Christopher J Michejda
-
Publication number: 20030198669Abstract: The present invention is an improvement in the treatment of migraine headaches. By administering dihydroergotamine alone (or a combination of DHE and caffeine) major limitations of past treatments are circumvented thereby allowing for higher efficacy and fewer side effects of treatment at lower doses.Type: ApplicationFiled: November 25, 2002Publication date: October 23, 2003Applicant: R.T. Alamo Ventures I, LLCInventors: Neal R. Cutler, Anthony DiSanto
-
Publication number: 20030187013Abstract: Crystalline form II of cabergoline, a pharmaceutical composition containing it and a process for its preparation are disclosed. The process may comprise crystallization from a solution of raw cabergoline in an organic solvent at low temperatures or submitting to a slurry procedure a mixture of cabergoline Forms I and II in a solvent at a temperature below about 30° C.Type: ApplicationFiled: January 16, 2003Publication date: October 2, 2003Inventors: Attilio Tomasi, Stefania Magenes, Giuliano Ramella, Mario Ungari, Marco Pandolfi
-
Publication number: 20030181462Abstract: A method of treatment or prevention of headache, migraine or cluster headaches, which method comprises co-administration of a therapeutically effective amount of the compound 1-[N2-[3,5-dibromo-N-[[4-(3,4-dihydro-2(1H)-oxochinazolin-3-yl)-1-piperidinyl]-carbonyl]-D-tyrosyl]-L-lysyl]-4-(4-pyridinyl)-piperazine[BIBN4096BS] or a physiologically acceptable salt thereof and a therapeutically effective amount of a second active antimigraine drug, particularly sumatriptan, zolmitriptan or dihydroergotamin or a physiologically acceptable salt thereof, as well as to the corresponding pharmaceutical compositions and the preparation thereof.Type: ApplicationFiled: August 13, 2002Publication date: September 25, 2003Applicant: Boehringer Ingelheim Pharma KGInventors: Henri Doods, Wolfgang Eberlein, Klaus Rudolf
-
Publication number: 20030181425Abstract: The present invention relates to pharmaceutical composition with lysergol as bioactive enhancer and bioavailability facilitator for broad-spectrum antibiotics. The present invention has direct implication in reducing the dosage of antibiotics while increasing the efficiency of absorption of nutritional elements.Type: ApplicationFiled: March 25, 2002Publication date: September 25, 2003Inventors: Suman Preet Singh Khanuja, Jai Shankar Arya, Santosh Kumar Srivastava, Ajit Kumar Shasany, Tiruppadiripuliyur Ranganathan Santha Kumar, Mahendra Pandurang Darokar, Sushil Kumar
-
Patent number: 6608064Abstract: The present invention is directed to the use of certain pyrido[1,2-a]-pyrazine derivatives, also described as bis-azabicyclic compounds and defined by the formula (I) herein, in the treatment of Parkinson's disease, attention deficit hyperactivity disorder and microadenomas in mammals, and to related compositions.Type: GrantFiled: May 3, 2001Date of Patent: August 19, 2003Assignee: Pfizer IncInventors: Stafford McLean, Stevin H. Zorn, Elisa R. Jackson
-
Publication number: 20030149067Abstract: A process for producing crystalline form I of cabergoline, which process comprises crystallization of the desired form from a toluene/diethyl ether mixture comprising raw cabergoline, followed by recovery and drying of the resulting crystals. A new solvate form V of cabergoline, useful as an intermediate, is also provided.Type: ApplicationFiled: February 3, 2003Publication date: August 7, 2003Inventors: Attilio Tomasi, Stefania Magenes, Mario Ungari, Giuliano Ramella, Gianfranco Pallanza
-
Publication number: 20030139420Abstract: The invention relates generally to the use of pharmaceutical compositions to increase milk production alone or in combination with certain biological active ingredients. Specifically, the method relates to the use of pharmaceutical compositions that will act on the feedback of the intrinsic regulatory pathway in the mammalian mammary gland. The present invention provides for as a method of increasing bovine milk production as well as a method of correcting certain human lactation abnormalities. Preferably, the compounds used in the methods of the present invention are one or more active agents capable of inhibiting peripheral aromatic amino acid decarboxylase (AADC) enzymes, peripheral tryptophan hydroxylase (TPH) enzymes, peripheral serotonin (5-HT) enzymes, or a combination of enzymes thereof.Type: ApplicationFiled: January 22, 2003Publication date: July 24, 2003Inventor: Nelson D. Horseman
-
Publication number: 20030130266Abstract: The present invention relates generally to pharmacological methods for the prevention of amelioration of sleep-related breathing disorders via administration of agents or combinations of agents that possess serotonin-related pharmacological activity.Type: ApplicationFiled: October 31, 2002Publication date: July 10, 2003Inventors: Miodrag Radulovacki, David W. Carley
-
Publication number: 20030114476Abstract: The present invention is directed to improved formulations for dihydroergotamine in which the drug is present at a concentration of at least 2.9 mM. The invention encompasses methods for using these formulations in treating patients for migraine headaches and the packaging of formulation into prefilled syringes for self-administration by patients.Type: ApplicationFiled: October 29, 2002Publication date: June 19, 2003Applicant: POZEN Inc.Inventors: John R. Plachetka, Donna Gilbert
-
Patent number: 6572879Abstract: Composition of matter for application to a body surface or membrane to administer pergolide by permeation through the body surface or membrane, the composition comprising pergolide to be administered, at a therapeutically effective rate, alone or in combination with a permeation enhancer or mixture. Also disclosed are drug delivery devices containing the pergolide or pergolide and enhancer composition and methods for the transdermal administration of the pergolide and pergolide/enhancer composition.Type: GrantFiled: June 7, 1995Date of Patent: June 3, 2003Assignee: Alza CorporationInventors: Su Il Yum, Melinda K. Nelson, Patricia S. Campbell
-
Publication number: 20030091513Abstract: A method for preparing a formulation containing nanoparticles of a compound is described. The method includes forming the compound into nanoparticles and then delivering the nanoparticles directly to a collection media. The collection media is a desired component of the formulation.Type: ApplicationFiled: October 3, 2002Publication date: May 15, 2003Inventors: Nahed M. Mohsen, Thomas A. Armer
-
Publication number: 20030092725Abstract: The present invention provides, in one embodiment, a method of normalizing the timing of sexual response in a mammal comprising the administration of an amount of a central nervous system sexual response initiator in an amount sufficient to produce genital vasodilation but less than the amount required to produce effective vasocongestive arousal. The method is applicable not only to adjusting or normalizing the timing of sexual response in humans, but in the breeding of valuable commercial animals such as horses, cattle, sheep, swine and the like and domesticated pets such as dogs and cats.Type: ApplicationFiled: May 20, 2002Publication date: May 15, 2003Inventors: Jeremy P.W. Heaton, Michael A. Adams
-
Patent number: 6559161Abstract: The invention provides compounds of formula (I) wherein R1 represents a hydrogen atom, an alkyl group having from 1 to 6 carbon atoms, a hydroxy group, an alkoxy group having from 1 to 6 carbon atoms, a halogen atom, a nitro group, an amino group, a monoalkylamino group wherein the alkyl moiety has from 1 to 6 carbon atoms, a dialkylamino group wherein each alkyl moiety may be the same or different and each has from 1 to 6 carbon atoms, a dialkoxyamino group wherein each alkoxy moiety may be the same or different and each has from 1 to 6 carbon atoms, an alkanoyalmino group having from 1 to 20 carbon atoms or an alkanesulfonylamino group having from 1 to 6 carbon atoms; R2 represents a hydrogen atom or an alkyl group having from 1 to 6 carbon atoms; and R3 represents a hydrogen atom, an alkyl group having from 1 to 6 carbon atoms or an alkoxy group having from 1 to 6 carbon atoms; and pharmaceutically acceptable salts thereof.Type: GrantFiled: May 9, 2002Date of Patent: May 6, 2003Assignee: Universidad de BarcelonaInventors: Mercedes Alvarez, Lidia Feliu, Dolores Garcia Gravalos, Jose Luis Fernandez-Puentes
-
Patent number: 6555548Abstract: The present invention provides for methods for the treatment of fibromyalgia syndrome or chronic fatigue syndrome by the administration of cabergoline-type compounds or a salt of said compound.Type: GrantFiled: May 30, 2002Date of Patent: April 29, 2003Assignee: Pharmacia & Upjohn CompanyInventors: Robert B. McCall, Robert Clyde Marshall, David W. Robertson, Thomas M. Ashley
-
Publication number: 20030078273Abstract: The treatment of addictive disorders, psychoactive substance use disorders, intoxication disorders, inhalation disorders, alcohol addiction, tobacco addiction, and nicotine addiction using a heterocyclic amine, a phenylazacycloalkane, a cabergoline, or an aromatic bicyclic amine active agent, or a pharmaceutically acceptable derivative or salt of any said active agent is described herein.Type: ApplicationFiled: November 15, 2002Publication date: April 24, 2003Inventors: Richard W. Anderson, Sylvia S. McBrinn, David W. Robertson, Robert C. Marshall
-
Patent number: 6548493Abstract: The present invention is directed to certain novel compounds represented by structural Formula (I) or pharmaceutically acceptable salt forms thereof, wherein R1, R5, R6a, R6b, R7, R8, R9, X, b, k, m, and n, and the dashed lines are described herein. The invention is also concerned with pharmaceutical formulations comprising these novel compounds as active ingredients and the use of the novel compounds and their formulations in the treatment of certain disorders. The compounds of this invention are serotonin agonists and antagonists and are useful in the control or prevention of central nervous system disorders including obesity, anxiety, depression, psychosis, schizophrenia, sleep disorders, sexual disorders, migraine, conditions associated with cephalic pain, social phobias, and gastrointestinal disorders such as dysfunction of the gastrointestinal tract motility.Type: GrantFiled: June 15, 2000Date of Patent: April 15, 2003Assignee: Bristol-Myers Squibb Pharma CompanyInventors: Albert J. Robichaud, Taekyu Lee, Wei Deng, Ian S. Mitchell, Wenting Chen, Christopher D. McClung, Emilie J. B. Calvello, David M. Zawrotny
-
Patent number: 6545011Abstract: This invention relates to compounds, pharmaceutical compositions, and methods of using the disclosed compounds for inhibiting PARP.Type: GrantFiled: July 2, 2001Date of Patent: April 8, 2003Assignee: Guilford Pharmaceuticals Inc.Inventors: Jia-He Li, Jie Zhang, Vincent J. Kalish
-
Publication number: 20030045539Abstract: This invention discloses new uses and treatments involving cabergoline, pramipexole and new combinations of cabergoline plus pramipexole used to treat patients. Here we disclose the use of cabergoline or pramipexole to treat PSP and MSA. Also disclosed is a combination treatment of cabergoline and pramipexole provided concurrently to a patient in need thereof for the treatment of various central nervous system diseases and in particular for the treatment of Parkinson's Disease (PD), but also for PSP and MSA.Type: ApplicationFiled: October 16, 2002Publication date: March 6, 2003Inventor: Baltazar Gomez-Mancilla
-
Publication number: 20030036548Abstract: A method of treating anhedonia in a patient in need thereof, comprising administering to the patient an effective amount of a dopamine agonistType: ApplicationFiled: August 6, 2002Publication date: February 20, 2003Applicant: Boehringer Ingelheim Pharma KGInventors: Erich Lehr, Joachim Mierau, Michael P. Pieper
-
Publication number: 20030022910Abstract: The present invention is an improvement in the treatment of migraine headaches. By administering dihydroergotamine across the oral mucosa, major limitations of past treatments are circumvented thereby allowing for higher efficacy and fewer side effects of treatment at lower doses.Type: ApplicationFiled: April 26, 2002Publication date: January 30, 2003Applicant: R.T. Alamo Ventures I, Inc.Inventor: Neal R. Cutler
-
Publication number: 20030017994Abstract: The present invention is an improvement in the treatment of migraine headaches. By administering dihydroergotamine as a sublingual spray or aerosol, major limitations of past treatments are circumvented thereby allowing for higher efficacy and fewer side effects of treatment at lower doses.Type: ApplicationFiled: April 26, 2002Publication date: January 23, 2003Applicant: R.T. Alamo Ventures I, Inc.Inventor: Neal R. Cutler
-
Publication number: 20030012740Abstract: The present invention relates to the delivery of compounds for the treatment of Parkinsons through an inhalation route. Specifically, it relates to aerosols containing antiparkinsonian drugs that are used in inhalation therapy. In a composition aspect of the present invention, the aerosol comprises particles comprising at least 5 percent by weight of an antiparkinsonian drug. In a method aspect of the present invention, an antiparkinsonian drug is delivered to a mammal through an inhalation route. The method comprises: a) heating a composition, wherein the composition comprises at least 5 percent by weight of an antiparkinsonian drug to form a vapor; and, b) allowing the vapor to cool, thereby forming a condensation aerosol comprising particles, which is inhaled by the mammal.Type: ApplicationFiled: May 20, 2002Publication date: January 16, 2003Inventors: Joshua D. Rabinowitz, Alejandro C. Zaffaroni
-
Publication number: 20030008005Abstract: The present invention is an improvement in the treatment of migraine headaches. By administering dihydroergotamine sublingually, major limitations of past treatments are circumvented thereby allowing for higher efficacy and fewer side effects of treatment at lower doses.Type: ApplicationFiled: July 5, 2001Publication date: January 9, 2003Applicant: R.T. Alamo Ventures, Inc.Inventor: Neal R. Cutler
-
Patent number: 6503920Abstract: This invention discloses new uses and treatments involving cabergoline, pramipexole and new combinations of cabergoline plus pramipexole used to treat patients. Here we disclose the use of cabergoline or pramipexole to treat PSP and MSA. Also disclosed is a combination treatment of cabergoline and pramipexole provided concurrently to a patient in need thereof for the treatment of various central nervous system diseases and in particular for the treatment of Parkinson's Disease (PD), but also for PSP and MSA.Type: GrantFiled: November 6, 2000Date of Patent: January 7, 2003Assignee: Pharmacia & Upjohn CompanyInventor: Baltazar Gomez-Mancilla
-
Publication number: 20020187985Abstract: Disclosed are methods for modifying or regulating at least one of glucose or lipid metabolism disorders which comprises administering to a human or vertebrate subject a D1 dopamine agonist in conjunction with a dopamine D2 agonist where the conjoined administration is effective to improve at least one of the following lipid and glucose metabolic indices: body weight, body fat, plasma insulin, plasma glucose and plasma lipid, and plasma lipoprotein. In preferred embodiments, the administration of the D1 dopamine agonist and the D2 dopamine agonist is conducted at a predetermined time.Type: ApplicationFiled: September 10, 2001Publication date: December 12, 2002Inventor: Anthony H. Cincotta
-
Patent number: 6492332Abstract: This invention relates to a method of inhibiting tumor cell adhesion, pain, and inflammation at a wound during a surgical procedure by delivering an irrigation solution containing a tumor cell anti-adhesion agent and a plurality of additional agents to an operative site during the surgical procedure. In addition, methods of inhibiting tumor cell attachment and implantation during a surgical procedure as well as inhibiting tumor metastasis during a surgical procedure are also provided.Type: GrantFiled: September 11, 2000Date of Patent: December 10, 2002Assignee: Omeros CorporationInventors: Gregory A. Demopulos, Pamela Pierce-Palmer, Jeffrey M. Herz, Darrell L. Tanelian
-
Publication number: 20020173505Abstract: A compound having agonist activity to the 5-HT4 receptor for use as a medicament and the use of said compound in the manufacture of a medicament for use in therapeutic or prophylactic treatment of disorders involving bronchocontraction of a human or animal body is described, as well as methods of treatment, wherein said compounds are administered. Further, a compound having antagonist activity to the 5-HT2a receptor for use as a medicament and the use of said compound in the manufacture of a medicament for use in therapeutic or prophylactic treatment or disorders involving bronchocontraction of a human or animal body is described, as well as methods of treatment, wherein said compounds are administered.Type: ApplicationFiled: October 29, 2001Publication date: November 21, 2002Inventor: Staffan Skogvall